When chemists design drug candidates, shape matters enormously. Many active pharmaceutical ingredients contain branched carbon structures-points where the molecular chain forks in a specific direction ...
In March 2026, Codexis reported that Q4 2025 revenue rose to US$38.92 million with net income of US$9.6 million, while full-year revenue reached US$70.39 million alongside a reduced net loss and new ...
Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway ...
REDWOOD CITY, Calif., March 4, 2026 /PRNewswire/ -- Codexis, Inc. (CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has ...
GSK is continuing to bolster its siRNA portfolio by paying $40 million upfront for a pair of oligonucleotide therapies from China’s Frontier Biotechnologies. The companies didn’t offer many details ...
Living systems perform chemical transformations under conditions and with precision that synthetic chemistry cannot reach. As such, the field has increasingly moved toward bioinspired and ...
Founded in 1992, Sirna Therapeutics was one of the earliest biotechnology companies focused on developing therapeutics based on RNA interference (RNAi), specifically using small interfering RNA (siRNA ...
RNA interference using small interfering RNAs (siRNAs) has become a mainstay of functional gene characterization and has generated over a dozen FDA-approved therapeutics and drugs in late-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results